MYLAN ACQUIRES INDIAN GENERIC DRUG MAKER MATRIX LABS

OCTOBER 01, 2006

Mylan Laboratories moved into the international generic pharmaceutical market in a big way by announcing an agreement to acquire India's Matrix Labs. Under the agreement, Mylan will buy a 51.5% stake at Matrix under a complex formula that could drive the final cost as high as $736 million. Matrix Labs will remain a publicly traded company in India and will continue to operate independently of Mylan.

Matrix Labs, one of the 12 companies authorized to supply medicines to former President Bill Clinton's Clinton Foundation, is also one of India's leading suppliers of raw materials for use by other generic pharmaceutical manufacturers in India.



SHARE THIS SHARE THIS
0

Immunization Laws Around the Nation

Many areas of medicine that intersect with law and immunizations are associated with a very specific set of laws across the nation.  

 

Pharmacy Times Strategic Alliance
 

Pharmacist Education
Clinical features with downloadable PDFs


Next-Generation Pharmacist® Awards


3rd Annual Convenient Healthcare and Pharmacy Collaborative Conference


SIGN UP FOR THE PHARMACY TIMES NEWSLETTER
Personalize the information you receive by selecting targeted content and special offers.